Using modern molecular allergy vaccines based on recombinant allergens, recombinant allergen derivatives or allergen-derived peptides (128) will clearly be possible to eliminate the risk of inducing adaptive immunity to HSA by not including albumin and albumin-derived epitopes in the vaccines. Here, ALB is linked to Allergy.